Table 1 Baseline characteristics of the patients remaining in this study after 48 weeks of follow-up‡
SCG (n = 392) | CMG (n = 400) | Statistic | P-value | |
|---|---|---|---|---|
Sex N (%) | χ2 = 2.540 | 0.111 | ||
Male | 224 (57.2) | 206 (51.5) | ||
Age (years) | 35 (30–41) | 36 (31–41) | Z = 1.504 | 0.133 |
Marital status N (%) | χ2 = 2.466 | 0.291 | ||
Single | 40 (10.2) | 39 (9.8) | ||
Married | 310 (79.1) | 326 (81.4) | ||
Divorced/widowed | 42 (10.7) | 35 (8.8) | ||
Educational level N (%) | χ2 = 2.028 | 0.154 | ||
Illiterate | 280 (71.4) | 267 (66.7) | ||
Body mass index (kg/m2) | 21.8 (20.2–23.1) | 21.5 (19.7–23.6) | Z = − 76941 | 0.650 |
Route of infection N (%) | χ2 = 1.069 | 0.615 | ||
Intravenous drug use | 191 (48.7) | 188 (47.0) | ||
Heterosexual transmission | 198 (50.5) | 206 (51.5) | ||
Other | 3 (0.8) | 6 (1.5) | ||
World health organization clinical staging N (%) | χ2 = 3.909 | 0.142 | ||
Stage I | 50 (12.7) | 42 (10.5) | ||
Stage II | 336 (85.8) | 344 (86.0) | ||
Stage III | 6 (1.5) | 14 (3.5) | ||
Treatment regimen N (%) | χ2 = 2.847 | 0.416 | ||
AZT + 3TC + EFV | 65 (16.6) | 71 (17.8) | ||
AZT + 3TC + NVP | 15 (3.8) | 8 (2.0) | ||
TDF + 3TC + EFV | 304 (77.6) | 310 (77.5) | ||
TDF + 3TC + NVP | 8 (2.0) | 11 (2.7) | ||
Baseline human immunodeficiency virus RNA (Log10 cps/mL) | Z = 77730 | 0.835 | ||
Baseline CD4 + T cell count | 376 (258–523) | 354 (252–520) | Z = 75832 | 0.425 |